Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OsteoporeASX:OSX Days Sales Outstanding is 157.77 as of Dec. 2025, which is 29% above its 10-year median of 121.99. The stock has 7 warning signs investors should review. Among 812 Medical Devices & Instruments companies, Osteopore ranks worse than 87.44% on this metric.
Osteopore's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$1.30 Mil. Osteopore's Revenue for the
six
months ended in Dec. 2025 was A$1.50 Mil.
Hence, Osteopore's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 157.77.
The historical rank and industry rank for Osteopore's Days Sales Outstanding or its related term are showing as below:
ASX:OSX'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 85.67 Med: 121.99 Max: 321.15
Current: 134.12
During the past 8 years, Osteopore's highest Days Sales Outstanding was 321.15. The lowest was 85.67. And the median was 121.99.
ASX:OSX's Days Sales Outstanding is ranked worse than 87.44% of 812
companies
in the Medical Devices & Instruments industry
Industry Median: 65.165
vs ASX:OSX: 134.12
Osteopore's Days Sales Outstanding
increased
from Dec. 2024 (100.78) to Dec. 2025 (157.77).
Osteopore (ASX:OSX) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Osteopore Days Sales Outstanding Related Terms
Osteopore Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Osteopore's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:OSX vs ISRG, BDX, MDLN: Days Sales Outstanding Comparison
For the Medical Instruments & Supplies subindustry, Osteopore's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Osteopore Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Osteopore's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Osteopore's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 157.77 mean?
Osteopore (ASX:OSX) has a Days Sales Outstanding of 157.77 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Osteopore and its competitors. This is 29% above median its historical median of 121.99. Over the past decade, Osteopore's Days Sales Outstanding has ranged from 85.67 to 321.15. According to the industry distribution chart, Osteopore ranks #710 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 87.4%.
Is Osteopore's Days Sales Outstanding too high?
Osteopore's current Days Sales Outstanding of 157.77 is 29% above median its 10-year median of 121.99. Over the past 10 years, this metric has ranged from a low of 85.67 to a high of 321.15. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.17. Osteopore's value of 157.77 is 142.1% above this industry median. Based on the distribution chart, Osteopore ranks #710 out of 812 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Osteopore's Days Sales Outstanding compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Osteopore ranks #710 out of 812 companies for Days Sales Outstanding. This places Osteopore in the lower half of its industry. The industry median Days Sales Outstanding is 65.17. Osteopore's value of 157.77 is 142.1% above this benchmark. Historically, Osteopore's own Days Sales Outstanding has ranged from 85.67 to 321.15 over the past decade. While the company's 10-year median is 121.99 vs. the industry median of 65.17, Osteopore has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.17, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Osteopore's current Days Sales Outstanding of 157.77 is 142.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Osteopore and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Osteopore's current Days Sales Outstanding is 157.77, which is 29% above median its own 10-year median of 121.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Osteopore stock overvalued right now?
Based on GuruFocus' analysis, Osteopore (ASX:OSX) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 80% below its estimated fair value. The current Days Sales Outstanding is 157.77, which is 29% above median its 10-year median of 121.99 and 142.1% above the Medical Devices & Instruments industry median of 65.17. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Osteopore (ASX:OSX), the current Days Sales Outstanding is 157.77 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Osteopore Ltd is engaged in the production of 3D-printed bioresorbable implants that are used in conjunction with surgical procedures to assist bone healing. Its products include Osteoplug, which is a bioresorbable implant used for covering trephination burr holes in neurosurgery, and Osteomesh which is a bioresorbable implant used in craniofacial surgery. It operate in the high-growth regenerative medicine sector, where adoption continues to rise as healthcare systems increasingly embrace developed tissue-regenerative solutions. Business operating segments are based on the firm's geographical presence in Singapore and Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OSX has been successfully added to your 
